viewFSD Pharma

Buds & Duds: Cannabis stocks in the green as North American markets find their footing

Among the breakouts was FSD Pharma, which saw its shares improve by double digits

Cannabis stocks gaining graphic
The major marijuana indices turned positive on Wednesday

Cannabis stocks recovered ground Wednesday, as North American markets showed signs of life across the board.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, gained 1.7% to 83.2 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF rose 1.8% to C$7.21, while the OTCQX Cannabis index improved 2.7% to 334.1 points.


FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE), a pharmaceutical cannabis research company, saw its shares surge. 

The company accepted an invitation to ring the opening bell at the Canadian Securities Exchange (CSE) on Friday in celebration of becoming the first CSE-listed company to dual list on a major US exchange. 

FSD stock jumped nearly 12% to C$6.71 on the CSE and 16% to US$5.16 on the Nasdaq.

Canntab Therapeutics Limited (CSE:PILL) (OTCMKTS:CTABF) after earning a Health Canada Licence that allows them Processing & Sales for Medical Purposes.

Cannatb shares increased 7.4% to C$0.58.


There was no runaway laggard on Wednesday, but a handful of cannabis stocks were worse for the wear in the midweek.

Tilray Inc (NASDAQ:TLRY), a cannabis research, cultivation and distribution company, dropped 5.3% to US$12.33.

GW Pharmaceuticals plc (NASDAQ:GWPH), a cannabinoid pharmaceutical company, dipped 1.7% to US$100.20.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: FSD Pharma

Price: 2.35 CAD

Market: CSE
Market Cap: $34.88 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...


FSD Pharma aims to initiate a Phase 2 coronavirus treatment trial by end...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) (FRA:0K9A) CEO Raza Bokhari tells Proactive the group has submitted an Investigational New Drug (IND) application to the FDA for the use of its lead candidate FSD-201, or anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA), to treat...

on 09/10/2020

2 min read